TMTobias Menne

Tobias Menne

*This is an algorithmically generated author record based on publicly available information.

Tobias Menne has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

    by Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, et al.

    UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m 2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS). From 2011 to 2018, 143 patients were randomly assigned to SOC ( N = 75) or SOC + nelarabine ( N = 68). There was no significant difference in EFS between the treatment groups; HR 0.86 (95% CI 0.52–1.43) P = 0.57, EFS: 58.2% SOC versus 62.7% SOC + nelarabine. The severe adverse events and nonrelapse mortality rates did not differ between the arms; in particular, there was no difference in grade 3–4 neurotoxicity. The 3‐year cumulative incidence of relapse was 31% in the SOC arm versus 28.9% in the SOC+ nelarabine arm. Forty of 44 relapses (90.9%) occurred within 2 years of randomization; the median survival postrelapse was 5.7 months, with no difference by arm. Diagnostic samples were analyzed for level of differentiation arrest by analysis of the TCRg locus to detect the most immature cases through absence of biallelic TCRg deletion (ABD). There was a trend toward more relapses with ABD (37.3%) versus no ABD (19.5%), P = 0.066. Diagnostic samples ( N = 133) were analyzed for mutations in NOTCH1, FBXW7, NRAS, KRAS, and PTEN , with no significant differences in CR rates or survival in patients with wild‐type (WT) NOTCH1 or FBXW7 . The 12 patients with NRAS mutations had significantly inferior CR and EFS compared to patients with wild‐type NRAS .

  • Open Access

    MTV ‐guided radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T‐cell therapy

    by Andrea Kuhnl, S. Bouziana, S. F. Barrington, S. Galani, T. Menne, M. Northend, L. Stevens, S. Kamat, W. Osborne, R. Johnson, et al.


  • Open Access

    Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

    by Christopher P. Fox, William Townsend, John G. Gribben, Tobias Menne, Nagesh Kalakonda, Paula Williams, Farah Toron, Emma Tyas, Miranda Cooper, Joshua Rickards, et al.

    Autologous stem‐cell transplantation (ASCT) is standard therapy for relapsed/refractory large B‐cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression‐free survival (PFS) and event‐free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.


  • Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline

    by Renata Walewska, Toby A. Eyre, Sally Barrington, Jessica Brady, Paul Fields, Sunil Iyengar, Anurag Joshi, Tobias Menne, Nilima Parry‐Jones, Harriet Walter, et al.


  • Open Access

    Central Venous Access Devices for the Delivery of Systemic Anticancer Therapy: An Economic Evaluation

    by Robert Heggie, Nishant Jaiswal, Elaine McCartney, Jon Moss, Tobias Menne, Brian Jones, Kathleen Boyd, Eileen Soulis, Neil Hawkins, Olivia Wu


  • Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time

    by S. Boyle, C. Roddie, M. O'Reilly, T. Menne, J. Norman, A. Gibb, S. Lugthart, S. Chaganti, C. Gonzalez Arias, C. Jones, et al.

    Summary: The success of CD19 Chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) has been partially offset by toxicity and logistical challenges, which off‐the‐shelf agents like CD20xCD3 bispecific antibodies might potentially overcome. However, when using CAR T outcomes as the ʽstandard‐of‐care comparator̕ for relapsed/refractory (r/r) LBCL, a potential learning curve with implementing a novel, complex therapy like CAR T needs to be considered. To address this, we analysed 726 UK patients intended to be treated with CD19 CAR T for r/r LBCL and compared outcomes between the first year of the national CAR T programme (Era 1; 2019) and the more recent treatment era (Era 2; 2020–2022). We identified significant improvements for Era 2 versus Era 1 in dropout rate (17% vs. 27%, p = 0.001), progression‐free survival (1‐year PFS 50% vs. 32%, p < 0.001) and overall survival (1‐year OS 60% vs. 40%, p < 0.001). We also observed increased use of bridging therapy, improvement in bridging outcomes, more tocilizumab/corticosteroid use, reduced high‐grade cytokine release syndrome (4% vs. 9%, p = 0.01) and intensive care unit admissions (20% vs. 32%, p = 0.001). Our results demonstrate significant improvement in CAR T outcomes over time, highlighting the importance of using up‐to‐date clinical data when comparing CAR T against new treatment options for r/r LBCL.


  • CAR T in patients with large B‐cell lymphoma not fit for autologous transplant

    by A. Kuhnl, A. A. Kirkwood, C. Roddie, T. Menne, E. Tholouli, A. Bloor, C. Besley, S. Chaganti, W. Osborne, J. Norman, et al.

    Summary: Large B‐cell lymphoma (LBCL) patients with comorbidities and/or advanced age are increasingly considered for treatment with CD19 CAR T, but data on the clinical benefit of CAR T in the less fit patient population are still limited. We analysed outcomes of consecutive patients approved for treatment with axicabtagene ciloleucel (axi‐cel) or tisagenlecleucel (tisa‐cel) by the UK National CAR T Clinical Panel, according to fitness for autologous stem cell transplant (ASCT). 81/404 (20%) of approved patients were deemed unfit for ASCT. Unfit patients were more likely to receive tisa‐cel versus axi‐cel (52% vs. 48%) compared to 20% versus 80% in ASCT‐fit patients; p < 0.0001. The drop‐out rate from approval to infusion was significantly higher in the ASCT‐unfit group (34.6% vs. 23.5%; p = 0.042). Among infused patients, response rate, progression‐free and overall survival were similar in both cohorts. CAR T was well‐tolerated in ASCT‐unfit patients with an incidence of grade ≥3 cytokine release syndrome and neurotoxicity of 2% and 11%, respectively. Results from this multicentre real‐world cohort demonstrate that CD19 CAR T can be safely delivered in carefully selected older patients and patients with comorbidities who are not deemed suitable for transplant.


  • Top Cited Papers

    A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience

    by Andrea Kuhnl, Claire Roddie, Amy A. Kirkwood, Eleni Tholouli, Tobias Menne, Amit Patel, Caroline Besley, Sridhar Chaganti, Robin Sanderson, Maeve O'REilly, et al.

    Summary: CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory (r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national cohort of patients intended to be treated with CAR‐T in the UK. Consecutive patients with r/r LBCL approved for CAR‐T by the National CAR‐T Clinical Panel between December 2018 and November 2020 across all UK CAR‐T centres were included. 404/432 patients were approved [292 axicabtagene ciloleucel (axi‐cel), 112 tisagenlecleucel (tisa‐cel)], 300 (74%) received the cells. 110/300 (38.3%) patients achieved complete remission (CR) at 6 months (m). The overall response rate was 77% (52% CR) for axi‐cel, 57% (44% CR) for tisa‐cel. The 12‐month progression‐free survival was 41.8% (axi‐cel) and 27.4% (tisa‐cel). Median overall survival for the intention‐to‐treat population was 10.5 m, 16.2 m for infused patients. The incidence of grade ≥3 cytokine release syndrome and neurotoxicity were 7.6%/19.6% for axi‐cel and 7.9%/3.9% for tisa‐cel. This prospective RW population of CAR‐T eligible patients offers important insights into the clinical benefit of CD19 CAR‐T in LBCL in daily practice. Our results confirm long‐term efficacy in patients receiving treatment similar to the pivotal trials, but highlight the significance of early CAR‐T failure.


  • Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT

    by Olivia Wu, Elaine McCartney, Robert Heggie, Evi Germeni, James Paul, Eileen Soulis, Susan Dillon, Caoimhe Ryan, Moira Sim, Judith Dixon-Hughes, et al.

    Background: Venous access devices are used for patients receiving long-term chemotherapy. These include centrally inserted tunnelled catheters or Hickman-type devices (Hickman), peripherally inserted central catheters (PICCs) and centrally inserted totally implantable venous access devices (PORTs). Objectives: To evaluate the clinical effectiveness, safety, cost-effectiveness and acceptability of these devices for the central delivery of chemotherapy. Design: An open, multicentre, randomised controlled trial to inform three comparisons: (1) peripherally inserted central catheters versus Hickman, (2) PORTs versus Hickman and (3) PORTs versus peripherally inserted central catheters. Pre-trial and post-trial qualitative research and economic evaluation were also conducted. Setting: This took place in 18 UK oncology centres. Participants: Adult patients (aged ≥ 18 years) receiving chemotherapy (≥ 12 weeks) for either a solid or a haematological malignancy were randomised via minimisation. Interventions: Hickman, peripherally inserted central catheters and PORTs. Primary outcome: A composite of infection (laboratory confirmed, suspected catheter related and exit site infection), mechanical failure, venous thrombosis, pulmonary embolism, inability to aspirate blood and other complications in the intention-to-treat population. Results: Overall, 1061 participants were recruited to inform three comparisons. First, for the comparison of peripherally inserted central catheters (n = 212) with Hickman (n = 212), it could not be concluded that peripherally inserted central catheters were significantly non-inferior to Hickman in terms of complication rate (odds ratio 1.15, 95% confidence interval 0.78 to 1.71). The use of peripherally inserted central catheters compared with Hickman was associated with a substantially lower cost (–£1553) and a small decrement in quality-adjusted life-years gained (–0.009). Second, for the comparison of PORTs (n = 253) with Hickman (n = 303), PORTs were found to be statistically significantly superior to Hickman in terms of complication rate (odds ratio 0.54, 95% confidence interval 0.37 to 0.77). PORTs were found to dominate Hickman with lower costs (–£45) and greater quality-adjusted life-years gained (0.004). This was alongside a lower complications rate (difference of 14%); the incremental cost per complication averted was £1.36. Third, for the comparison of PORTs (n = 147) with peripherally inserted central catheters (n = 199), PORTs were found to be statistically significantly superior to peripherally inserted central catheters in terms of complication rate (odds ratio 0.52, 95% confidence interval 0.33 to 0.83). PORTs were associated with an incremental cost of £2706 when compared with peripherally inserted central catheters and a decrement in quality-adjusted life-years gained (–0.018) PORTs are dominated by peripherally inserted central catheters: alongside a lower complications rate (difference of 15%), the incremental cost per complication averted was £104. The qualitative work showed that attitudes towards all three devices were positive, with patients viewing their central venous access device as part of their treatment and recovery. PORTs were perceived to offer unique psychological benefits, including a greater sense of freedom and less intrusion in the context of personal relationships. The main limitation was the lack of adequate power (54%) in the non-inferiority comparison between peripherally inserted central catheters and Hickman. Conclusions: In the delivery of long-term chemotherapy, peripherally inserted central catheters should be considered a cost-effective option when compared with Hickman. There were significant clinical benefits when comparing PORTs with Hickman and with peripherally inserted central catheters. The health economic benefits were less clear from the perspective of incremental cost per quality-adjusted life-years gained. However, dependent on the willingness to pay, PORTs may be considered to be cost-effective from the perspective of complications averted. Future work: The deliverability of a PORTs service merits further study to understand the barriers to and methods of improving the service. Trial registration: This trial is registered as ISRCTN44504648. Funding: This project was funded by the National Institute for Health Research (NHIR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 47. See the NIHR Journals Library website for further project information.


  • Open Access

    Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

    by Adam Gibb, Sarah J. Pirrie, Kim Linton, Victoria Warbey, Kathryn Paterson, Andrew J. Davies, Graham P. Collins, Tobias Menne, Pamela McKay, Paul A. Fields, et al.

    Summary: Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety and efficacy of brentuximab vedotin (BV), in previously untreated patients with cHL unfit for standard treatment due to age, frailty or comorbidity. The primary outcome was complete metabolic response (CMR) by positron emission tomography/computed tomography after four BV cycles (PET4). The secondary outcomes included progression‐free survival (PFS), overall survival (OS), and toxicity. In all, 35 patients with a median age of 77 years and median total Cumulative Illness Rating Scale for Geriatrics (CIRS‐G) score of 6 were evaluable for toxicity and 31 for response. A median of four cycles were given (range one–16). In all, 14 patients required dose reduction due to toxicity and 11 patients stopped treatment due to adverse events (AEs). A total of 716 AEs were reported, of which 626 (88%) were Grade 1/2 and 27 (77%) patients had at least one AE Grade ≥3. At PET4, CMR was 25·8% [95% confidence interval (CI) 13·7–42.2%] and objective response rate 83·9% (95% CI 63·7–90·8%). Median PFS was 7·3 months (95% CI 5·2–9·0), and OS 19·5 months. Our results suggest that BV monotherapy is tolerable but suboptimal in the front‐line therapy of elderly or comorbid patients with cHL. Combining BV with other agents may be more effective.Trial Registration: Clinicaltrials.gov identifier: NCT02567851.